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ABST RACT 
The advent of sophisticated diagnostics has enabled the discovery of previously unknown arthropod-borne 
v iruses like Chikungunya. This infection has become increasingly prevalent in the last 10 years across the 
Indian Ocean and has been brought to media attention by a recent outbreak in the Caribbean. The outbreak 
has been aided by  a drastic rise in air travel, allowing infected individuals to transport the v irus to pre -
v iously unaffected regions. In addition, a recently documented viral mutation has allowed its transmission 
by  the Aedes albopictus mosquito, therefore facilitating outbreaks in Southern Europe and the USA. The 
duration and extent of the arthritis seen peri- and post infection has become a topic of academic interest. 
Although published data are largely observational, there has been a definite increase in original research 
focusing on this. Sy mptoms can persist for years, particularly in older patients with p re-existing medical 
conditions. The etiology is still not fully  understood, but v iral persistence and immune activation within 
sy novial fluid have been shown in mouse models. There have been no prospective clinical trials of treatment 
in humans; however, animal trials are in process. The mainstay of treatment remains anti-inflammatories 
and steroids where necessary . The clinical presentation seems to mimic common rheumatological 
conditions like rheumatoid arthritis; therefore recent recommendations suggest the use disease-modifying 
agents as a common practice for the specific syndrome. This review uses recent published data and draws 
on our own clinical experience to provide an overview of joint complications of Chikunguny a infection.  
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INT RODUCTION 
Chikunguny a v irus (CHIKV) is a mosquito -borne 
alpha v irus that has precipitated several large out-
breaks across the southern hemisphere in the last 
decade. First described in Tanzania in the 1950s, 
Chikunguny a, also known as break-bone fever, 
means “that which bends up” in the Makonde 
language. Following a few outbreaks in the 1960s 
and 1970s in Asia and Africa, the v irus re-emerged 
in 2005 and spread across the Indian Ocean. Since 
2014, over a million cases have been reported in the 
Americas and the Caribbean, with declining case 
numbers in 2016. Much of what we currently know 
about the disease was first published following a 
large outbreak on the island of La Réunion, affecting 
37 % of the entire population.1  
The v irus causes a self-limiting acute illness 
comprising of fever, rash, arthralgia, and my algia. 
Other complications, like multi-organ failure and 
neurological manifestations, have been described 
but are extremely rare. The most notable long-term 
complication is a chronic debilitating arthritis that 
causes considerable disability in certain groups. As 
we gain more experience with this disease, pub-
lished literature describing this manifestation has 
become more plentiful; however, little is understood 
about the pathophy siology  and optimal manage -
ment of this condition. This review will provide an 
update of current data and recommendations on 
Chikunguny a-related arthralgia. 
T HE VECTOR 
Chikunguny a is a zoonotic arbovirus that is trans-
mitted by  the Aedes mosquito. These are day-biting 
arthropods that breed in open water and can be 
found across Africa and Asia. Epidemics occur 
through human–mosquito transmission made 
possible by high-circulating viremia during acute in-
fection. Between epidemics, the life cy cle is main-
tained through primates and mainly Aedes aegypti 
mosquito. The genetic variation seen in this RNA 
v irus has allowed mutation of the v irus to enable 
transmission by the Aedes albopictus, an arthropod 
that is well established in the Americas and Europe.2 
This has facilitated the outbreaks of the last 10  
y ears, around the Indian Ocean and across the 
Caribbean, with an outbreak in Italy  in 2007  and 
cases in other parts of Europe.3 Subsequently, there 
are concerns that the v irus may , in time, cause 
further outbreaks across Europe and Northern 
America. 
DIAGNOST ICS 
Diagnostic techniques have improved significantly 
in recent y ears and can be grouped into molecular 
and serological tests. 
Molecular tests are most useful in the acute phase 
of illness. These use reverse transcriptase PCR assays 
to amplify  fragments of the CHIKV genome and can 
be used to quantify  fragments in real time. 4 A 
development in recent y ears has been the multiplex 
assay  on a chip that can simultaneously  detect 26 
tropical pathogens including CHIKV and dengue.5 
Serological assay s can be used to determine 
whether the patient has been previously  infected. 
These use enzy me-linked immunosorbent assay s 
(ELISAs) that capture IgM and IgG. Other tests in-
clude immunofluorescence and immunoblot assays 
for CHIKV proteins.4 More recently a rapid immu-
nochromatographic test has been developed that can 
detect CHIKV, best used in the first 5  days of illness, 
with a sensitiv ity of 89.4% and specificity of 94.4%.6 
This would allow rapid diagnosis at the point of 
care, therefore precluding the need for further 
investigations. 
CLINICAL COURSE OF T HE DISEASE 
The clinical illness has a relatively sho rt incubation 
period—ty pically  2–10 day s. Sudden-onset high 
fever is usually the first symptom and can last up to 
a week and can follow a biphasic course. Fever often 
precedes a maculo-papular rash over the trunk and 
extremities, headache, my algia,  and arthralgia. 
Ocular disease has been described in Malaysia from 
a few cases of anterior uveitis.7 More severe compli-
cations include nephritis, my ocarditis, meningo -
encephalitis, Guillain–Barré syndrome, and cranial 
nerve palsies that can occur during the acute illness 
or in subsequent months.4 It can be difficult to 
differentiate acute CHIKV infection from dengue; 
however, it has been suggested that thrombocy to -
penia is more indicative of dengue, whereas rash 
and arthralgia suggest CHIKV.8 It has also been 
noted that pregnant women infected with the virus 
in the last few day s of pregnancy are able to transmit 
the v irus to the baby, which can lead to severe en-
cephalopathy in the neonate and subsequent neuro-
disability, as demonstrated in a recent cohort study 
from La Réunion.9 
After the acute illness, which can last from 7  to 
10 day s, rheumatic sequelae can persist for months 
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to y ears. These can have broad clinical presentations 
and an, as y et, unclear etiology . 
CHIKUNGUNYA RHEUMAT ISM 
Musculoskeletal manifestations of disease have been 
shown to affect 4%–7 5% of those infected with 
CHIKV.4 These figures vary  widely  depending on 
baseline genetic susceptibility  of populations, 
cultural perceptions, and quality  of study .  
Arthralgia usually affects more than one joint, 
particularly  knees, ankles, hands, and wrists in a 
bilateral and sy mmetric distribution. 1 0 In some 
cohorts, over 50% of patients had arthralgia and 
clinically detectable joint swelling at 3 y ears after 
their acute infection.11,12 A 6-year retrospective study 
in La Réunion by  Javelle et al. looked at patients 
referred to a rheumatologist due to rheumatic 
sy mptoms lasting more than 4 months following 
CHIKV infection. Out of 159 cases, they found that 
59% met the criteria for de novo  chronic inflam-
matory rheumatism (CIR) like rheumatoid arthritis, 
spondy larthropathy, and undifferentiated polyarth-
ritis, and 31% had pre-existing rheumatic musculo-
skeletal disorders. Amongst those with de novo  
rheumatoid arthritis, 80% developed joint damage 
within 3–4 y ears. They  found that some patients 
remained sy mptomatic for 6–8 y ears. Patients that 
did not fit the CIR criteria presented most com-
monly  with bilateral distal poly arthralgia, fibro -
my algia, edema, and carpal tunnel syndrome.13 This 
finding was mirrored in a study from Sri Lanka from 
2006 where 21% of the total number of infected 
indiv iduals exhibited carpal tunnel sy ndrome. 1 4 
There have also been recent cases of patients pre-
senting with catastrophic antiphospholipid sy n-
drome and adult-onset Still’s disease.1 5 
Plasma markers of inflammation such as ESR 
and CRP are unreliable in predicting the severity of 
joint involvement. Javelle et al. found that only 2 out 
of 15 patients with spondylarthropathies were HLA-
B27  positive, both of whom had psoriasis. Rheuma-
toid factor (RF) or anti-citrullinated protein anti-
body  (ACPA) positiv ity  was found in 30% of 
patients, which was similar to other studies. 1 3 
Radiological imaging of affected joints showed 
erosions and joint space narrowing in a small cohort 
in La Réunion.1 6 Destructive lesions were more com-
monly  seen in those with an rheumatoid arthritis-
like presentation, with up to 80% affected in some 
cohorts.1 3 By  contrast, in our London cohort of 
CHIKV-infected returning travelers, we found pre-
dominantly joint effusions rather than synovitis on 
ultrasound examination (unpublished data).  Mag-
netic resonance imaging has similar findings to 
ultrasound with predominant joint effusion, sy n-
ovial thickening, tendonitis, and tenosy novitis. 1 7  
Risk factors for prolonged disease are age greater 
than 50 y ears, longer acute stage of illness (more 
than 15 days), and presence of other comorbidities.18 
A study  looking at predictors of rheumatism in the 
TELECHIK cohort of patients in La Réunion 
performed a multinomial logistic regression on the 
346 patients with declared rheumatic musculo -
skeletal pain. They found age greater than 45, severe 
rheumatic involvement at presentation (fever, more 
than six  joints affected, and four other rheumatic 
sy mptoms), and CHIKV -specific IgG titers were 
strong determinants of persistent musculoskeletal 
pain. The CHIKV-specific IgG titers were correlated 
to age, female gender, and severity of initial rheu-
matic sy mptoms. They concluded that the humoral 
immune response has a significant prognostic value; 
however, the adaptive immune response play s an 
important role in chronic manifestations. 1 0 
The etiology of the arthralgia is not fully  under-
stood. Research from mouse models comparing 
wild-ty pe and Rag1-deficient mice that lack T and B 
cells inoculated with CHIKV shows higher v iral 
levels in Rag1-deficient mice. This suggests the role 
of the adaptive immune system in host response and 
persistence of infection. In addition, tissues with 
high CHIKV RNA levels in these mice histologically  
exhibited synovitis, arthritis, and tendonitis, sug-
gesting that the arthritis is not mediated by  the 
adaptive immune system. The persistence of CHIKV 
was tissue-specific as sampling of other organs 
showed rapid clearance of the virus when compared 
with joints and skeletal muscle, in which it persisted 
for at least 16 weeks.1 9 
Samples from a human sy novial biopsy  taken 
from an affected indiv idual with chronic joint dis-
ease showed joint infiltration with natural killer 
cells, CD4 cells, and CHIKV RNA in macrophages. 
Histologically there was sy novial hypertrophy, vas-
cular proliferation, and perivascular macrophage 
infiltration similar to that seen in rheumatoid arth-
ritis.20 This suggests that the CHIKV arthralgia is 
etiologically similar to other inflammatory arthrop-
athies and, as such, a similar treatment approach 
can be adopted. 
As disease can last for y ears, there is ev idence 
that quality of life of indiv iduals is adversely affect-
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ed. A study  by  Couturier et al. followed up CHIKV -
infected individuals for 2 y ears following diagnosis. 
Of the 391  patients that answered the survey, 55% of 
patients considered themselves to have not 
recovered from CHIKV at a median of 23.4 months 
post diagnosis. Assessments of quality of life using 
well-known tools like SF-36 (short term health 
survey), GHQ-12 (general health questionnaire), and 
AIMS2-SF (arthritis impact measurement scale) 
were performed at regular intervals and compared 
with age- and gender-matched scores. Those who 
considered themselves as unrecovered had much 
lower scores than recovered participants. 1 8 In 
addition, there is ev idence of the financial burden 
that this can have—a study  from La Réunion has 
estimated the annual cost at €34 million.1 2 
T REATMENT AND PREVENTION OF 
INFECTION 
There are currently  no licensed treatments for 
CHIKV infection. Several drugs have been found to 
have modest effect by targeting viral replication or 
host cellular components. Although these mainly  
target acute v iral infection, little is known of the 
effect of antiv iral treatments on chronic infection. 
Drugs that inhibit v iral entry include chloroquine 
and arbidol. Chloroquine, historically  an anti-
malarial drug, has been thought to be effective 
against chronic CHIKV since the early  1980s; 
however, a recent trial using it as treatment in acute 
infection has shown it to be ineffective.21,22 Arbidol 
is a licensed antiv iral in Russia, and arbidol 
analogues have been found to have anti-CHIKV 
activ ity .23 
A potent inhibitor of viral protein translation has 
been found to be harringtonine and its more stable 
analogue, homoharringtonine. This drug has mini-
mal cy totoxic effects and has recently been licensed 
in the USA for treatment of acute my eloid leu-
kemia.24 
Most effective of the antiv iral drugs are those 
that target v iral genome replication. Ribavirin has 
been used most widely as it is licensed for treatment 
of respiratory syncytial v irus in infants. Ribavirin in 
combination with interferon has been shown to act 
sy nergistically in preventing CHIKV replication.25 
My cophenolic acid appears to be more effective 
than ribavirin in vitro as described by Khan et al. in 
2011.26 Another anti-metabolite that is effective in 
vitro  is 6-azauridine as it inhibits sy nthesis of py r-
imidines.22,25 Favipiravir has been shown to protect 
mice against CHIKV -caused disease as a potent 
poly merase inhibitor.27  
Although these drugs have displayed some effica-
cy , they can only reduce viral replication by 50% in 
mouse models and have not yet moved to more rele-
vant testing platforms for chronic CHIKV infection. 
An alternative to these antiviral drugs is human 
poly - or monoclonal antibodies. The use of human 
poly valent antibodies taken from human plasma 
donors in the convalescent phase of CHIKV infec -
tion showed full protective efficacy  in mouse 
models. This effect was completely  therapeutic 8 
hours post infection and reduced as time passed.27 
Prophy lactic administration of neutralizing mono-
clonal antibodies to Rag1 -deficient mice prevented 
them from developing persistent infection and was 
even effective in clearing CHIKV from tissues when 
administered later on in infection.1 9 This work 
suggests the potential for monoclonal neutralizing 
antibodies in prevention of CHIKV -associated 
arthralgia in endemic areas. 
Further preventive measures such as vaccines 
against CHIKV have not y et been licensed but have 
been a goal since the 1960s. The CHIK-IRES vaccine 
is an attenuated vaccine derived from a strain of virus 
from La Réunion in 2006. This has been engineered 
to prevent it from replicating in the Aedes mosquito 
and, following recent trials in non-human primates, 
is planned for phase I trials. Another promising 
vaccine has implemented induced neutralizing anti-
bodies and v irus-like particles (VLPs) which are 
immunogenic in non-human primates and has 
entered into phase II trials (NCT02562482).27 It will 
be important to show that these vaccines can have 
long-lasting protection against the v irus and are 
robust against wild-type v irus and different vectors. 
The release of a genetically engineered mosquito 
carry ing lethal genes (Release of Insects with 
Dominant Lethal Gene [RIDL]) has also been 
investigated for prevention of infection. However, 
there have been concerns that this measure in Aedes 
aegypti in Panama has allowed the mutation of 
CHIKV to be transmitted by the Aedes albopictus.28 
In addition, it may  even drive selection of more 
v irulent and severe v iruses.2 Another approach has 
been to infect mosquitoes with the Wolbachia 
bacterium, which is thought to interfere with 
mosquito replication. 
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MANAGEMENT OF CHIKV RHEUMAT ISM 
Management of CHIKV rheumatic disease has 
traditionally used a generic approach to this diverse 
group of clinical presentations. Javelle et al. recently 
suggested grouping patients according to their clin-
ical sy ndrome and tailoring treatment accordingly.13 
The mainstay  of treatment has been with anti-
inflammatory  drugs, phy siotherapy , and short 
courses of oral steroids; however, clinical withdraw-
al of these treatments can be difficult. Evidence from 
La Réunion suggested that loco -regional disease 
responded well to physiotherapy  and to localized 
joint injections. Carpal tunnel syndrome was treated 
with NSAIDs and with phy siotherapy . Urate -
lowering drugs can be effective, as can bone -
strengthening measures such as v itamin D. 1 3 
In those with persistent symptoms, there is little 
ev idence on effective therapies. Several disease -
modify ing drugs (DMARDs) have been trialed with 
vary ing success. Chloroquine has some antiv iral 
effect but has not been found to be more effective 
than other anti-inflammatories like meloxicam in 
acute and chronic CHIKV arthralgia.29 Methotrexate 
has been widely  used, particularly in patients who 
present with a systemic polyarthritis. A recent study 
showed that 75% of patients had a positive clinical 
response to this.13 Sulfasalazine has been shown to 
have good clinical efficacy , particularly  when 
combined with methotrexate.30 
There are no good-quality trials assessing the use 
of biologic drugs in CHIKV rheumatic disease. There 
are data to suggest that serum cytokines are raised 
in patients with persistent symptoms, including IL-6 
and IL-8.31  In addition, a number of cases report 
successful use of biologic immuno modulatory  
agents such as inflix imab or etanercept in patients 
with severe disease.32 
Bindarit is a small-molecule indazolic derivative 
that has anti-inflammatory  properties through 
inhibiting chemokine sy nthesis. This has been 
trialed in CHIKV mouse studies to reduce joint dam-
age and inflammation and improve bone health.33,34 
These studies showed reduced macrophage 
infiltration of joints and therefore reduced tissue 
damage and disease sy mptoms and also reduced 
osteoclastic activity. As it is less immunosuppressive 
than more widely used biologic agents such as anti-
TNF drugs, it has the potential to be a safe treat-
ment to prevent v iral-induced joint damage and 
bone loss. 
CONCLUSION 
Since its initial description in the 1950s, there have 
been multiple large Chikungunya outbreaks world-
wide. Mutation of the v irus to allow carriage by  
Aedes albopictus has enabled transmission of the 
v irus in prev iously unexposed areas, substantially  
increasing the at-risk population. The recent warn-
ings in relation to Zika v irus have emphasized the 
increasing risk from Aedes-borne v iruses to the 
general population. 
The growing body  of ev idence regarding the 
debilitating chronic arthritis following Chikungunya 
infection has illustrated trends in presentation. It 
has also allowed certain conclusions to be drawn 
regarding treatment strategies from the experience 
of clinicians worldwide. As the arthritis often has a 
strong semblance to well-described rheumatic pre-
sentations, it has often been treated as such, with 
reasonable outcomes. The importance of maintain-
ing a holistic approach and considering quality  of 
life is ev ident, particularly as long-term sequelae are 
more frequently  seen in older patients with pre -
existing medical comorbidities. Although the mor-
tality  associated with this infection is small, the 
morbidity and burden of disease is large, affecting 
several million people worldwide. With a rapidly  
expanding area of endemicity , rheumatologists 
should be prepared to see more chronic arboviral 
arthritides in their day-to-day clinics. More research 
and awareness is necessary  in order to develop 
better treatment strategies for such patients.  
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